Skip to main content

Newborn Screening for Hereditary Tyrosinemia Type I in Québec: Update

  • Chapter
  • First Online:
Hereditary Tyrosinemia

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 959))

Abstract

Hereditary tyrosinemia type I (HTI) is a rare autosomal recessive disorder caused by a fumarylacetoacetate hydrolase (FAH) deficiency. If untreated, its acute form is characterized by hepatic failure, renal dysfunction and neurological crisis, and may lead to death. Due to a genetic founder effect in the French-Canadian population, the prevalence of HTI is increased in the province of Quebec (1/19 819), with the IVS12 + 5G>A (1062 + 5G>A) splice site mutation responsible for more than 90% of mutated alleles. Universal newborn screening for (HT1) was thus established in 1970, and close to four million infants have been tested so far, allowing to identify 185 of the 190 affected newborns. During the 1970–1997 period, 2,249,000 newborns were screened at 3–7 days of life on dried filter paper blood spots by tyrosine (Tyr) concentration followed by indirect colorimetric semi-quantitative and quantitative (Q) succinylacetone (SA) testing (red blood cells δ-aminolevulinate dehydratase inhibition), with immunoreactive FAH as the confirmatory test. This approach allowed to identify 118 of 123 affected newborns. In 1998, owing to earlier hospital discharge and increased rate of breastfeeding, four cases were missed within the same year as the discriminating power of blood Tyr became inadequate. Thus, the screening algorithm was modified: indirect semi-quantitative SA measurement became the first-tier test between 1998 and 2014, and direct SA measurement by tandem mass spectrometry (MS/MS) was implemented in 2014, followed by indirect quantitative SA measurement as second tier test. Confirmation is performed by plasmatic amino acid profile and molecular testing. During the 1998–2016 period, more than 1,5 million neonates have been tested (90% sampled between 24 and 48 h of life): 67 of the 67 HTI cases were identified. Both indirect and direct SA measurement as the initial HTI screening test proved to be highly sensitive and specific, with positive and negative predicting value of 79% and 100% respectively.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Andermann A, Blancquaert I, Beauchamp S, Costea I (2011) Guiding policy decisions for genetic screening: developing a systematic and transparent approach. Public Health Genomics 14(1):9–16. doi:10.1159/000272898

    Article  CAS  PubMed  Google Scholar 

  • Angileri F, Bergeron A, Morrow G, Lettre F, Gray G, Hutchin T, Ball S, Tanguay RM (2015) Geographical and ethnic distribution of mutations of the fumarylacetoacetate hydrolase gene in hereditary tyrosinemia type 1. JIMD Rep 19:43–58. doi:10.1007/8904_2014_363

    Article  PubMed  PubMed Central  Google Scholar 

  • De Braekeleer M, Larochelle J (1990) Genetic epidemiology of hereditary tyrosinemia in Quebec and in Saguenay-Lac-St-Jean. Am J Hum Genet 47(2):302–307

    PubMed  PubMed Central  Google Scholar 

  • Grenier A, Laberge C (1996) Neonatal screening for tyrosinemia type I and early sampling. In: Proceedings of the Third International Society for Neonatal Screening, Boston, Oct 20–23

    Google Scholar 

  • Grenier A, Belanger L, Laberge C (1976) alpha1-Fetoprotein measurement in blood spotted on paper: discriminating test for hereditary tyrosinemia in neonatal mass screening. Clin Chem 22(7):1001–1004

    CAS  PubMed  Google Scholar 

  • Grompe M, St-Louis M, Demers SI, al-Dhalimy M, Leclerc B, Tanguay RM (1994) A single mutation of the fumarylacetoacetate hydrolase gene in French Canadians with hereditary tyrosinemia type I. N Engl J Med 331(6):353–357. doi:10.1056/NEJM199408113310603

    Article  CAS  PubMed  Google Scholar 

  • Halvorsen S (1980) Screening for disorders of tyrosine metabolism. In: Bickel H, Guthrie R, Hammerson G (eds) Neonatal screenings for inborn errors of metabolism. Springer, New York

    Google Scholar 

  • JMG W, Jungner G, World Health Organization (1968) Principles and practice of screening for disease, Public Health Papers, vol 34. World Health Organization, Geneva

    Google Scholar 

  • Laberge C (1969) Hereditary tyrosinemia in a French Canadian isolate. Am J Hum Genet 21(1):36–45

    CAS  PubMed  PubMed Central  Google Scholar 

  • Laberge C, Dallaire L (1967) Genetic aspects of tyrosinemia in the Chicoutimi region. Can Med Assoc J 97(18):1099–1101

    CAS  PubMed  PubMed Central  Google Scholar 

  • Laberge C, Grenier A, Valet JP, Morissette J (1990) Fumarylacetoacetase measurement as a mass-screening procedure for hereditary tyrosinemia type I. Am J Hum Genet 47(2):325–328

    CAS  PubMed  PubMed Central  Google Scholar 

  • Laberge AM, Michaud J, Richter A, Lemyre E, Lambert M, Brais B, Mitchell GA (2005) Population history and its impact on medical genetics in Quebec. Clin Genet 68(4):287–301. doi:10.1111/j.1399-0004.2005.00497.x

    Article  PubMed  Google Scholar 

  • Mitchell GA, Grompe M, Lambert M, Tanguay RM (2001) Hypertyrosinemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease. McGraw Hill, New York, pp 1777–1806

    Google Scholar 

  • Poudrier J, St-Louis M, Lettre F, Gibson K, Prevost C, Larochelle J, Tanguay RM (1996) Frequency of the IVS12 + 5G–>A splice mutation of the fumarylacetoacetate hydrolase gene in carriers of hereditary tyrosinaemia in the French Canadian population of Saguenay-Lac-St-Jean. Prenat Diagn 16(1):59–64. doi:10.1002/(SICI)1097-0223(199601)16:1<59::AID-PD810>3.0.CO;2-D

    Article  CAS  PubMed  Google Scholar 

  • Scott CR (2006) The genetic tyrosinemias. Am J Med Genet C: Semin Med Genet 142C(2):121–126. doi:10.1002/ajmg.c.30092

    Article  CAS  Google Scholar 

  • van Spronsen FJ, Thomasse Y, Smit GP, Leonard JV, Clayton PT, Fidler V, Berger R, Heymans HS (1994) Hereditary tyrosinemia type I: a new clinical classification with difference in prognosis on dietary treatment. Hepatology 20(5):1187–1191

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Yves Giguère .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Giguère, Y., Berthier, MT. (2017). Newborn Screening for Hereditary Tyrosinemia Type I in Québec: Update. In: Tanguay, R. (eds) Hereditary Tyrosinemia. Advances in Experimental Medicine and Biology, vol 959. Springer, Cham. https://doi.org/10.1007/978-3-319-55780-9_13

Download citation

Publish with us

Policies and ethics